REYON Pharmaceutical Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for REYON Pharmaceutical.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 38.2% |
| Inkomstengroei | n/a |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | None |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Geen updates
Recent updates
REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit
Oct 18
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings
Mar 31Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend
May 08Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?
Feb 28Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend
Jan 20
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?
Dec 12How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?
Nov 24In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat REYON Pharmaceutical onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 6/30/2024 | 148,991 | -104 | -22,225 | 2,657 | N/A |
| 3/31/2024 | 151,056 | 1,902 | -20,609 | 4,252 | N/A |
| 12/31/2023 | 151,071 | 3,583 | -20,227 | 8,645 | N/A |
| 9/30/2023 | 150,584 | 8,456 | -19,038 | 12,971 | N/A |
| 6/30/2023 | 152,043 | 10,614 | -21,686 | 12,848 | N/A |
| 3/31/2023 | 153,907 | 7,503 | -32,911 | 9,962 | N/A |
| 12/31/2022 | 154,039 | 7,359 | -54,404 | 8,729 | N/A |
| 9/30/2022 | 152,549 | 4,816 | -63,949 | 9,463 | N/A |
| 6/30/2022 | 150,237 | 2,774 | -82,042 | 12,848 | N/A |
| 3/31/2022 | 146,329 | 6,265 | -103,331 | 15,345 | N/A |
| 12/31/2021 | 142,801 | 5,412 | -105,312 | 11,685 | N/A |
| 9/30/2021 | 139,414 | 5,650 | -107,713 | 8,450 | N/A |
| 6/30/2021 | 135,893 | 6,518 | -93,909 | 5,607 | N/A |
| 3/31/2021 | 131,303 | 4,843 | -70,265 | 2,981 | N/A |
| 12/31/2020 | 130,034 | 3,844 | -47,287 | 4,599 | N/A |
| 9/30/2020 | 129,738 | 1,720 | -39,699 | 2,314 | N/A |
| 6/30/2020 | 129,684 | 2,165 | -35,337 | 6,798 | N/A |
| 3/31/2020 | 131,581 | 2,165 | -53,806 | -12,825 | N/A |
| 12/31/2019 | 131,558 | 4,946 | -63,564 | -12,184 | N/A |
| 9/30/2019 | 128,267 | 1,478 | -56,438 | -5,595 | N/A |
| 6/30/2019 | 125,963 | 594 | -74,593 | -12,861 | N/A |
| 3/31/2019 | 124,192 | 3,299 | -47,790 | 5,730 | N/A |
| 12/31/2018 | 122,990 | 1,343 | -27,748 | 11,449 | N/A |
| 9/30/2018 | 122,850 | 7,021 | -25,025 | 8,456 | N/A |
| 6/30/2018 | 123,936 | 9,643 | 2,584 | 11,159 | N/A |
| 3/31/2018 | 124,150 | 9,073 | N/A | 15,186 | N/A |
| 12/31/2017 | 126,253 | 12,887 | N/A | 16,764 | N/A |
| 9/30/2017 | 126,748 | 13,195 | N/A | 14,348 | N/A |
| 12/31/2016 | 121,847 | 10,701 | N/A | 9,471 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if A102460's forecast earnings growth is above the savings rate (2.6%).
Winst versus markt: Insufficient data to determine if A102460's earnings are forecast to grow faster than the KR market
Hoge groeiwinsten: Insufficient data to determine if A102460's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if A102460's revenue is forecast to grow faster than the KR market.
Hoge groei-inkomsten: Insufficient data to determine if A102460's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if A102460's Return on Equity is forecast to be high in 3 years time